Souhaitez-vous accéder aux communiqués récents ?

The current indications of soficitinib under development are strategically positioned within the vast dermatology market.

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at...

Totaligent (OTCID: TGNT) executed a binding LOI for the acqui-hire of Aetherium Medical (https://www.aetheriummedical.com/)

MONTRÉAL, 12 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la «Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement...

Cannara (TSXV: LOVE; OTCQX: LOVFF) hosts an investor webcast Feb 19, 2026 at 2:00 PM ET. Hear CFO Nicholas Sosiak + live Q&A—register now free

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data...

Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data...

Etienna Bio, Inc., announces the formation of its Scientific Advisory Board with the appointment of two internationally recognized leaders in cell biology